CoreRx, Inc. Acquires Societal CDMO, Inc.

McKesson Corporation Acquires Controlling Interest in Core Ventures

June 3, 2025

Healthcare Services

McKesson Corporation completed the acquisition of an approximate 70% controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures) for about $2.49 billion. The venture was established by Florida Cancer Specialists & Research Institute (FCS), whose physicians retained an approximate 30% interest; FCS remains independently owned and joins McKesson's The US Oncology Network to strengthen community-based oncology care and expand access to clinical development and local cancer services.

Bend Bioscience Unites CoreRx and Societal CDMO Under Single Bend Bioscience Brand

September 4, 2024

Pharmaceuticals

Bend Bioscience has unified CoreRx and Societal CDMO under the Bend Bioscience brand to form an integrated contract development and manufacturing organization (CDMO). The consolidation combines CoreRx’s formulation development expertise, Societal CDMO’s scalable cGMP manufacturing and packaging capabilities, and Bend Bioscience’s research and technology to offer end-to-end development-to-commercialization services across facilities in Bend, Oregon; Clearwater, Florida; and Gainesville, Georgia.

ARCHIMED and CDPQ Recapitalize Corealis Pharma

May 24, 2022

Pharmaceuticals

Transatlantic PE firm ARCHIMED, joined by Caisse de dépôt et placement du Québec (CDPQ), has recapitalized Corealis Pharma, a Laval, Quebec–based CDMO specializing in oral solid dosage formulation and clinical-supply manufacturing. The recapitalization will fund expansion of GMP-compliant facilities, R&D capabilities and accelerate growth for Corealis to serve small- and mid-sized biotech and pharma customers.

Recro Pharma Acquires IRISYS (San Diego)

August 13, 2021

Pharmaceuticals

Recro Pharma (NASDAQ: REPH) acquired San Diego–based CDMO IRISYS for approximately $49.85 million in cash, stock and a seller promissory note, transforming Recro into a bi‑coastal, full‑service CDMO. The acquisition expands Recro's capabilities (including aseptic fill/finish and lyophilization), diversifies its client base and adds near‑term revenue and backlog.

CoreRx Acquires Nucleo Life Sciences

May 24, 2021

Pharmaceuticals

CoreRx, Inc. has acquired Nucleo Life Sciences, a boutique CDMO based in San Rafael, California, expanding CoreRx’s US West Coast development presence and formulation capabilities. The deal, supported by CoreRx’s majority owner NovaQuest Private Equity and other shareholders, will integrate Nucleo’s Fast-to-Clinic formulation expertise (including spray-dried dispersions and NucleLoad) into CoreRx’s development and manufacturing platform.

NovaQuest Private Equity Acquires CoreRx, Inc.

January 19, 2021

Pharmaceuticals

NovaQuest Private Equity acquired CoreRx, Inc., a Clearwater, Florida–based contract development and manufacturing organization (CDMO). Affiliates of Signet Healthcare Partners will retain a minority stake; Goldman Sachs Specialty Lending Group provided debt financing. NovaQuest said the investment will support continued growth and capability expansion of CoreRx's clinical and commercial CDMO services.